Therapeutic Asset Ratings
462 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]-
Neoplasm
Ikena Oncology
P1
C
(36)
Bgb-26808
Neoplasm
BeOne Medicines
P1
C
(36)
Bgb-A3055
Neoplasm
BeiGene
P1
C
(36)
Bgb-B167
Neoplasm
BeiGene
P1
C
(36)
Bgb-R046
Neoplasm
BeOne Medicines
P1
C
(36)
bgc515
Neoplasm
BridGene Biosciences Inc.
P1
C
(36)
Bhv-1530
Neoplasm
Biohaven Therapeutics Ltd.
P1
C
(36)
Biottt001
Neoplasm
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
P1
C
(36)
Bl-B16D1
Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
Bl-M02D1
Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
Bl-M08D1
Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
Bl-M09D1
Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
Bl-M17D1
Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
Bl-M24D1
Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
bm230
Neoplasm
Suzhou Biomissile Pharmaceuticals Co., Ltd.
P1
C
(36)
bp1001-a
Neoplasm
Bio-Path Holdings, Inc.
P1
C
(36)
Bpi-442096
Neoplasm
Betta Pharmaceuticals Co., Ltd.
P1
C
(36)
Bpi-452080
Neoplasm
Betta Pharmaceuticals Co., Ltd.
P1
C
(36)
Brodalumab
Neoplasm
Brian Henick, MD
P1
C
(36)
Bsi-082
Neoplasm
Lei Zheng
P1
C
(36)
BYON4228
Neoplasm
Byondis B.V.
P1
C
(36)
c5252
Neoplasm
ImmVira Pharma Co. Ltd
P1
C
(36)
Cadvec
Neoplasm
Baylor College of Medicine
P1
C
(36)
can1012
Neoplasm
Canwell Biotech Limited
P1
C
(36)
can2109
Neoplasm
Canwell Biotech Limited
P1
C
(36)
Showing 276 to 300 of 462 assets
Previous
Page 12 of 19
Next
